210 related articles for article (PubMed ID: 8255359)
1. Experimental Parkinson's disease in monkeys. Effect of ergot alkaloid derivative on lipid peroxidation in different brain areas.
Marzatico F; Café C; Taborelli M; Benzi G
Neurochem Res; 1993 Oct; 18(10):1101-6. PubMed ID: 8255359
[TBL] [Abstract][Full Text] [Related]
2. Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys.
Mochizuki H; Imai H; Endo K; Yokomizo K; Murata Y; Hattori N; Mizuno Y
Neurosci Lett; 1994 Feb; 168(1-2):251-3. PubMed ID: 8028787
[TBL] [Abstract][Full Text] [Related]
3. MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in primates.
Zuddas A; Oberto G; Vaglini F; Fascetti F; Fornai F; Corsini GU
J Neurochem; 1992 Aug; 59(2):733-9. PubMed ID: 1629743
[TBL] [Abstract][Full Text] [Related]
4. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy.
Morissette M; Goulet M; Soghomonian JJ; Blanchet PJ; Calon F; Bédard PJ; Di Paolo T
Brain Res Mol Brain Res; 1997 Oct; 49(1-2):55-62. PubMed ID: 9387863
[TBL] [Abstract][Full Text] [Related]
5. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey.
Pifl C; Schingnitz G; Hornykiewicz O
Neuroscience; 1991; 44(3):591-605. PubMed ID: 1754053
[TBL] [Abstract][Full Text] [Related]
6. Short- and long-term changes in striatal and extrastriatal dopamine uptake sites in the MPTP-treated common marmoset.
Gnanalingham KK; Milkowski NA; Smith LA; Hunter AJ; Jenner P; Marsden CD
Eur J Pharmacol; 1995 Apr; 277(2-3):235-41. PubMed ID: 7493614
[TBL] [Abstract][Full Text] [Related]
7. Brain α7 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients.
Morissette M; Morin N; Grégoire L; Rajput A; Rajput AH; Di Paolo T
Biochem Pharmacol; 2016 Jun; 109():62-69. PubMed ID: 27038656
[TBL] [Abstract][Full Text] [Related]
8. Coenzyme Q, peroxidation and cytochrome oxidase features after parkinson's-like disease by MPTP toxicity in intra-synaptic and non-synaptic mitochondria from Macaca fascicularis cerebral cortex and hippocampus: action of dihydroergocriptine.
Battino M; Littarru GP; Gorini A; Villa RF
Neurochem Res; 1996 Dec; 21(12):1505-14. PubMed ID: 8953566
[TBL] [Abstract][Full Text] [Related]
9. Neurotensin receptors and dopamine transporters: effects of MPTP lesioning and chronic dopaminergic treatments in monkeys.
Goulet M; Morissette M; Grondin R; Falardeau P; Bédard PJ; Rostène W; Di Paolo T
Synapse; 1999 Jun; 32(3):153-64. PubMed ID: 10340626
[TBL] [Abstract][Full Text] [Related]
10. Antioxidant responses and lipid peroxidation following intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats: increased susceptibility of olfactory bulb.
Franco J; Prediger RD; Pandolfo P; Takahashi RN; Farina M; Dafre AL
Life Sci; 2007 Apr; 80(20):1906-14. PubMed ID: 17382353
[TBL] [Abstract][Full Text] [Related]
11. The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease.
Pifl C; Schingnitz G; Hornykiewicz O
Neurosci Lett; 1988 Oct; 92(2):228-33. PubMed ID: 3263594
[TBL] [Abstract][Full Text] [Related]
12. Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice.
Zou L; Xu J; Jankovic J; He Y; Appel SH; Le W
Neurosci Lett; 2000 Mar; 281(2-3):167-70. PubMed ID: 10704769
[TBL] [Abstract][Full Text] [Related]
13. The evolution of nigrostriatal neurochemical changes in the MPTP-treated squirrel monkey.
Irwin I; DeLanney LE; Forno LS; Finnegan KT; Di Monte DA; Langston JW
Brain Res; 1990 Oct; 531(1-2):242-52. PubMed ID: 1981162
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotective effects of alpha-dihydroergocryptine against damages in the substantia nigra caused by severe treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Bernocchi G; Gerzeli G; Scherini E; Vignola C
Acta Neuropathol; 1993; 85(4):404-13. PubMed ID: 7683168
[TBL] [Abstract][Full Text] [Related]
15. Changes in the local cerebral metabolic rate for glucose in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) primate model of Parkinson's disease.
Schwartzman RJ; Alexander GM
Brain Res; 1985 Dec; 358(1-2):137-43. PubMed ID: 3878182
[TBL] [Abstract][Full Text] [Related]
16. The influence and the mechanism of docosahexaenoic acid on a mouse model of Parkinson's disease.
Ozsoy O; Seval-Celik Y; Hacioglu G; Yargicoglu P; Demir R; Agar A; Aslan M
Neurochem Int; 2011 Oct; 59(5):664-70. PubMed ID: 21736911
[TBL] [Abstract][Full Text] [Related]
17. GDNF improves dopamine function in the substantia nigra but not the putamen of unilateral MPTP-lesioned rhesus monkeys.
Gerhardt GA; Cass WA; Huettl P; Brock S; Zhang Z; Gash DM
Brain Res; 1999 Jan; 817(1-2):163-71. PubMed ID: 9889359
[TBL] [Abstract][Full Text] [Related]
18. Expression of peroxisome proliferator-activated receptor-gamma in the substantia nigra of hemiparkinsonian nonhuman primates.
Swanson C; Emborg M
Neurol Res; 2014 Jul; 36(7):634-46. PubMed ID: 24620964
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective effects of madecassoside in early stage of Parkinson's disease induced by MPTP in rats.
Xu CL; Qu R; Zhang J; Li LF; Ma SP
Fitoterapia; 2013 Oct; 90():112-8. PubMed ID: 23876367
[TBL] [Abstract][Full Text] [Related]
20. [Lipid peroxidation in the caudate nuclei in experimental parkinsonian syndrome].
Kucherianu VG; Atadzhanov MA; Nikushkin EV; Zagorevskiĭ VA; Sharkova LM
Biull Eksp Biol Med; 1989 Jan; 107(1):39-41. PubMed ID: 2783652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
